Osteopontinc isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity. Brum MCM, Dos Santos Guimaraes I, Ferreira LB, Rangel LBA, et al. Oncol Rep 2020 Dec 1. doi: 10.3892/or.2020.7877.

Read + Share

Amedeo Smart

Independent Medical Education

Brum MCM, Dos Santos Guimaraes I, Ferreira LB, Rangel LBA, et al. Osteopontinc isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity. Oncol Rep 2020 Dec 1. doi: 10.3892/or.2020.7877.
PMID: 33416171